<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00837213</url>
  </required_header>
  <id_info>
    <org_study_id>EVF0701</org_study_id>
    <nct_id>NCT00837213</nct_id>
  </id_info>
  <brief_title>Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne</brief_title>
  <official_title>Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stiefel, a GSK Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin
      vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment
      of moderate acne
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy and safety of Benzoyl peroxide  used in combination with clindamycin
      vs. Benzoyl peroxide  used in combination with clindamycin and doxycycline once daily in the
      treatment of moderate acne
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percent Change in Inflammatory Acne Lesions From Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline to week 16 in inflammatory acne lesions (pustules/papules)(chest and back)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16.</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in Non-inflammatory acne lesions (whiteheads and blackheads)(chest and back) from baseline to week 16.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change in Total Acne Lesion Counts From Baseline to Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change from baseline to week 16 in total acne lesions (inflammatory + non-inflammatory)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Investigator Global Assessment (IGA)</measure>
    <time_frame>Baseline, Weeks 4, 8,12, and 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Investigator Global Assessment (IGA) Average values chest and back.
IGA scale:
0 - Clear
0.5 - Clear/almost clear
Almost Clear
1.5- Almost Clear/Mild
Mild
2.5- Mild/Moderate
Moderate
3.5- Moderate/Severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in inflammatory lesion counts (chest and back)from Baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in non-inflammatory lesions (chest and back) from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12</measure>
    <time_frame>Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent change in total lesions (chest and back) from baseline to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Particpants With IGA Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator Global Assessment (IGA) at Week 16 based on the Investigator Global Assessment
IGA:
0 - Clear
0.5 - Clear/almost clear
Almost Clear
1.5- Almost Clear/Mild
Mild
2.5- Mild/Moderate
Moderate
3.5- Moderate/Severe</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>BPO with clindamycin foam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzoyl peroxide (BPO) wash with clindamycin foam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BPO + clindamycin foam + doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzoyl peroxide (BPO) wash with clindamycin foam and doxycycline capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide with clindamycin</intervention_name>
    <description>Benzoyl  peroxide wash - Clindamycin foam</description>
    <arm_group_label>BPO with clindamycin foam</arm_group_label>
    <other_name>Acne</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide with clindamycin and doxycycline</intervention_name>
    <description>Benzoyl  peroxide wash - Clindamycin foam - Doxycycline  capsules</description>
    <arm_group_label>BPO + clindamycin foam + doxycycline</arm_group_label>
    <other_name>Acne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with acne vulgaris . Able to understand the requirements of
             the study and sign informed consent/HIPAA authorization forms.

        Exclusion Criteria:

          -  Known hypersensitivity to any of the components of the study drugs or used of
             prohibited medications or any medical condition that contraindicate the subject's
             participation in the clinical study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology, Cosmetic and Laser Surgery</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Skin &amp; Cancer Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 12, 2011</lastchanged_date>
  <firstreceived_date>February 4, 2009</firstreceived_date>
  <firstreceived_results_date>April 7, 2010</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri A. Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>Acne</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
